



(12) Translation of new
European patent specification
After opposition procedure

(11) NO/EP 2621517 B2

NORWAY

(19) NO
(51) Int Cl.

A61K 38/24 (2006.01)

A61P 15/08 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2015.11.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.06.17
(45)	Decision of the opposition in EPO	2023.10.11
	Decision of the opposition in NIPO	2024.01.15
(86)	European Application Nr.	11778689.7
(86)	European Filing Date	2011.09.28
(87)	The European Application's Publication Date	2013.08.07
(30)	Priority	2010.09.29, EP, 10251681
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Ferring B.V., Polaris Avenue 144, 2132 JX Hoofddorp, Nederland
(72)	Inventor	ARCE SAEZ, Joan Carlos, Søvej 100, Dragør 2791, Danmark
(74)	Agent or Attorney	AWA NORWAY AS, Postboks 1052 Hoff, 0218 OSLO, Norge

(54)	Title	COMPOSITION FOR USE IN TREATING INFERTILITY
(56)	References Cited:	WO-A1-00/67778, EP-A2- 0 788 799, US-A1- 2004 248 784, WO-A1-01/00227, FILICORI et al.: "The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction", Human Reprod. Update, vol. 8, no. 6, 2002, pages 543-557, Van Horne et al/ (2007) Fertil Steril, 88(4) 1010-1013 ASHKENAZI J ET AL: "The value of GnRH analogue therapy in IVF in women with unexplained infertility.", HUMAN REPRODUCTION (OXFORD, ENGLAND) AUG 1989 LNKD- PUBMED:2528570, vol. 4, no. 6, August 1989 (1989-08), pages 667-669, XP002666590, ISSN: 0268-1161 MANNAERTS B: "A DOUBLE-BLIND, RANDOMIZED, DOSE-FINDING STUDY TO ASSESS THE EFFICACY OF THE GONADOTROPHIN-RELEASING HORMONE ANTAGONIST GANIRELIX (ORG 37462) TO PREVENT PREMATURE LUTEINIZING HORMONE SURGES IN WOMEN UNDERGOING OVARIAN STIMULATION WITH RECOMBINANT FOLLICLE STIMULATING HORMONE (PUREGON). THE GANIRELIX", HUMAN REPRODUCTION, OXFORD UNIVERSITY PRESS, GB, vol. 13, no. 11, 1 January 1998 (1998-01-01), pages 3023- 3031, XP000876538, ISSN: 0268-1161, DOI: DOI:10.1093/HUMREP/13.6.1461 Filicori et al (2005); Fertil Steril 84(2) 275-284

FILICORI M ET AL: "STIMULATION AND GROWTH OF ANTRAL OVARIAN FOLLICLES BY SELECTIVE LH ACTIVITY ADMINISTRATION IN WOMEN", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 87, no. 3, 1 March 2002 (2002-03-01), pages 1156-1161, XP008004363, ISSN: 0021-972X, DOI: DOI:10.1210/JC.87.3.1156

PAULSON R J ET AL: "ADDITION OF A GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONIST AND EXOGENOUS GONADOTROPINS TO UNSTIMULATED IN VITRO FERTILIZATION (IVF) CYCLES: PHYSIOLOGIC OBSERVATIONS AND PRELIMINARY EXPERIENCE", JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, PLENUM PUBLISHING, US, vol. 11, no. 1, 1 January 1994 (1994-01-01), pages 28-32, XP000876515, ISSN: 1058-0468, DOI: DOI:10.1007/BF02213694

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Et produkt omfattende det follikkelstimulerende hormonet (FSH) og human choriongonadotropin (hCG) til anvendelse i behandlingen av infertilitet ved kontrollert ovariestimulering for å utvikle en eller flere toppkvalitets embryoer, der
5 FSH er for administrering i en dose på 75 til 250 IU FSH per dag ved oppstart på dag én av behandlingen og som fortsetter i to til tjue dager; og hCG'et er for administrering i en dose på 140 til 190 IU hCG per dag ved oppstart på dag én av behandlingen og som fortsetter i to til tjue dager.
2. Et produkt til anvendelse ifølge krav 1, der behandlingen inkluderer et videre
10 trinn der det fryses ned minst ett resulterende toppkvalitets embryo.